Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222667 | 1.00 | NOS3 (0.50) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 | |
| Cyanide SCHEMBL28324057 | 0.94 | NOS3 (0.45) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL24703386 | 0.85 | NOS3 (0.45) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL14647750 | 0.84 | NOS3 (0.48) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL4328494 | 0.84 | NOS3 (0.48) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL12349148 | 0.83 | PIK3CD (0.57) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL6469008 | 0.82 | NOS3 (0.46) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23201276 | 0.82 | NOS3 (0.46) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL23478507 | 0.82 | NOS3 (0.46) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30929411 | 0.82 | NOS3 (0.46) | NOS3NOS2KDM4EHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263431-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | ORGANON R&D FINLAND LTD (FI) | 2025-08-21 | — | — | US | disclosed |
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| CN-120152973-A | Protein tyrosine phosphatase inhibitors, compositions, and methods of use | 百时美施贵宝公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-03-06 | — | — | US | disclosed |
| EP-4464693-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Daewoong Pharmaceutical Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| EP-3891167-B1 | ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS INHIBITORS OF 17-HSD1 | Organon R&D Finland Oy (FI) | 2024-11-13 | — | — | EP | disclosed |
| US-20240309043-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | ORGANON R&D FINLAND LTD (FI) | 2024-09-19 | — | — | US | disclosed |
| CN-118632836-A | Novel aminobenzene derivative having cancer cell growth inhibitory effect and preventive or therapeutic pharmaceutical composition containing the same as active ingredient | 株式会社大熊制药 | 2024-09-10 | — | — | CN | disclosed |
| CN-118324761-A | USP inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
| EP-1483265-B1 | PURINE DERIVATIVES AS KINASE INHIBITORS | LILLY CO ELI (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1667980-A1 | 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| CN-1639165-A | Purine derivatives as kinase inhibitors | LILLY CO ELI (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| WO-2003084931-A1 | 5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| CN-1210105-A | Process for preparation of 2,5-disubstituted pyridines | HOFFMANN LA ROCHE (CH) | 1999-03-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | NOS3 2141/4885NOS2 2940/4885KDM4E 796/4885 |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | NOS3 2095/4885NOS2 2060/4885KDM4E 1308/4885 |
| US-20240309043-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | HSD17B11, NR5A1, CYP17A1 | NOS3 871/4885NOS2 966/4885KDM4E 1654/4885 |
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | MKI67, CCNB1, ALDH7A1 | NOS3 710/4885NOS2 348/4885KDM4E 889/4885 |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | NOS3 4096/4885NOS2 3310/4885KDM4E 1491/4885 |
| US-20250263431-A1 | THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVES | HSD17B11, NR5A1, CYP17A1 | NOS3 871/4885NOS2 966/4885KDM4E 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.